BigHat Bio
Jack Shumway is currently a Business Development Intern at BigHat Biosciences, contributing to asset evaluation and opportunity prioritization for one of FierceBiotech's 2024 "Fierce 15" cohort. Simultaneously, Jack is involved with the Stanford Office of Technology Licensing in the High Impact Technology Fund, collaborating with experts to accelerate the commercialization of Stanford-based innovations. Prior experience includes serving as a Graduate Research Assistant at the Hoover Institution, where emphasis was placed on the strategic understanding of biology, and as a Corporate Venture Capital MBA Intern at Ajinomoto Corporate Venture Capital, leading due diligence efforts in the cell therapy landscape. Jack also gained early-stage deep tech investing experience as an Investor with Boom Capital. Jack is pursuing a graduate degree at Stanford University Graduate School of Business following a Bachelor's degree in Genome Sciences/Genomics from Davidson College.
This person is not in any teams
This person is not in any offices
BigHat Bio
1 followers
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.